Glaukos Corporation

GKOSNYSEUSD
125.00 USD
3.31 (2.72%)AT CLOSE (11:59 AM EDT)
124.95
0.05 (0.04%)
POST MARKET (AS OF 08:15 PM EDT)
Post Market
AS OF 08:15 PM EDT
124.95
0.05 (0.04%)
🔴Market: CLOSED
Open?$122.67
High?$128.05
Low?$120.61
Prev. Close?$121.69
Volume?1.4M
Avg. Volume?1.1M
VWAP?$125.05
Rel. Volume?1.26x
Bid / Ask
Bid?$120.49 × 300
Ask?$149.52 × 100
Spread?$29.03
Midpoint?$135.01
Valuation & Ratios
Market Cap?7.1B
Shares Out?58.7M
Float?55.2M
Float %?94.0%
P/E Ratio?N/A
P/B Ratio?10.65
EPS?-$3.22
Dividend?0.00%
Ex-Dividend?N/A

Glaukos Corporation (GKOS) is currently trading at $125.00. The technical outlook is "Buy" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, GKOS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Employees
1.1K
Market Cap
7.1B
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed
2015-06-25
Address
1 GLAUKOS WAY
ALISO VIEJO, CA 92656
Phone: 949-367-9600
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+1/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
100
Momentum?
87
Short Sent.?
64
Piotroski F-Score?2/9Weak
Altman Z-Score?18.20Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?5.99%Elevated
Short Interest?3.3M
Days to Cover?4.3
Free Float55.2M
Avg Daily Volume775.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?5.43Strong
Quick Ratio?4.73Strong
Cash Ratio?1.17Strong
Debt/Equity?0.10Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A
P/B?
Peers
100
S&P
18
10.65HIGH
P/S?
Peers
100
S&P
3
12.96HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-45.3CHEAP
EV/Sales?
Peers
100
S&P
6
12.90HIGH
Returns & Efficiency
ROE?
S&P
6
-28.2%WEAK
ROA?
S&P
3
-21.2%WEAK
Cash Flow & Enterprise
FCF?$-35088000
Enterprise Value?$7.1B
Fundamentals ratios updated end of day